IBRX Stock — ImmunityBio, Inc.

ImmunityBio, Inc. (IBRX)

Updated October 16, 2026.

IBRX is a Stock. Total return is -73.5% over the past 11.2 years, 411.9 points behind SPY at 338.4%.

ImmunityBio is a San Diego-based biotechnology company developing immunotherapies designed to activate the patient's immune system against cancer and infectious diseases, with platforms including cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's lead product, Anktiva, is FDA-approved for treating BCG-unresponsive non-muscle invasive bladder cancer, and it maintains collaboration agreements with the National Cancer Institute and other partners. The company does not currently have an established distribution schedule.

IBRX performance versus SPY

Price and return data through 2026-10-16.

Total return is -73.5% over the past 11.2 years, 411.9 points behind SPY at 338.4%. Over the past year its total return — price change plus distributions reinvested — is 262.9%. Its deepest 1-year drawdown was 42.3%.

IBRX key facts

Asset type

Stock

Asset class

Equity

Inception date

07/28/2015

Distribution frequency

None

Last close

$9.18 (as of 2026-10-16)

Market cap

$9,729,296,986

Average volume

21485000.0

Beta

0.03

Payout ratio

0.0%

Forward P/E

123.4568

EPS

$-1.00

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IBRX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 42.3%.

Who may consider IBRX — and who may not

It is a weaker fit for investors who need monthly cash flow (IBRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on IBRX

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions